Massachusetts Financial Services Co. MA Purchases 20,035 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Massachusetts Financial Services Co. MA boosted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 215.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,314 shares of the company's stock after purchasing an additional 20,035 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.05% of Twist Bioscience worth $1,324,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TWST. Signaturefd LLC lifted its position in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares during the last quarter. EdgeRock Capital LLC acquired a new position in shares of Twist Bioscience during the second quarter worth approximately $43,000. Blue Trust Inc. boosted its position in shares of Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after acquiring an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in shares of Twist Bioscience in the second quarter worth $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after acquiring an additional 381 shares during the period.

Insider Buying and Selling

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,730 shares of the business's stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total value of $81,206.20. Following the transaction, the chief executive officer now owns 495,523 shares of the company's stock, valued at approximately $23,259,849.62. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Robert F. Werner sold 1,448 shares of the firm's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the sale, the chief accounting officer now owns 45,620 shares of the company's stock, valued at approximately $2,034,652. This trade represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock worth $4,391,151 in the last quarter. 3.92% of the stock is owned by corporate insiders.

Twist Bioscience Stock Up 4.3 %

Twist Bioscience stock traded up $1.98 during mid-day trading on Thursday, hitting $48.32. 691,981 shares of the company were exchanged, compared to its average volume of 950,291. Twist Bioscience Co. has a 1-year low of $23.07 and a 1-year high of $60.90. The business has a fifty day moving average of $43.78 and a 200 day moving average of $46.22. The company has a market capitalization of $2.87 billion, a PE ratio of -13.42 and a beta of 1.78.

Wall Street Analyst Weigh In

TWST has been the subject of a number of research reports. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. JPMorgan Chase & Co. upped their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a report on Monday, August 5th. TD Cowen reissued a "buy" rating and set a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday. Scotiabank boosted their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a research report on Tuesday, November 19th. Finally, Evercore ISI raised their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of "Moderate Buy" and a consensus target price of $51.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.